John Martin - Gilead

John Martin - Gilead
Total Compensation: $15.6 million

Details: Martin picked up a raise over 2010, when he pulled down $14.2 million. His base salary went up by less than $100,000, but the value of his option awards grew by more than $1 million, topping his then-high gross of $14.7 in 2009.

While Gilead ($GILD) has long found success with its HIV treatments, the company is trying to diversify, starting with last year's $11 billion buyout of Pharmasset, netting that company's promising hepatitis C drug PSI-7977, currently moving through clinical trials. Gilead reported 20% growth in sales of its flagship HIV drugs, and it boosted its R&D spending by 80% in Q1, dropping $458 million on its pipeline, Reuters reported. There has been some backlash, though, as the company came under fire last year for its pricing of HIV meds, some of which can cost as much as $20,000 per year, making them near cost-prohibitive for some providers.

John Martin - Gilead
Read more on

Suggested Articles

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.